Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenalisib in relapsed/refractory hematologic malignancies
NCT02017613Phase 1Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Nov 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tenalisib in hematologic malignancy, B cell lymphoma and T-cell lymphoma, sponsored by Rhizen Pharmaceuticals AG. Primary endpoints: Maximum Tolerated Dose at 28 days and Pharmacokinetics at 28 days. Started Nov 2013; status: completed.
02
Drugs
tenalisib
03
Conditions
hematologic malignancyB cell lymphomaT-cell lymphoma
Beyond the preview
Go deeper on NCT02017613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017613.